NICE Seeks More Data From Abbott On Humira In Psoriatic Arthritis
This article was originally published in The Pink Sheet Daily
Executive Summary
U.K. agency’s preliminary appraisal on cost effectiveness does not call for recommending adalimumab.
You may also be interested in...
U-Turn: NICE Recommends Rituximab, Humira In Arthritis Indications After Second Review
U.K. agency reverses unfavorable preliminary opinions based on submissions from Roche and Abbott.
As Seagen Matures, CEO Siegall Talks About Moving The Growth Goalposts
The ADC specialist could have a fourth cancer drug on the market this year and is preparing for its first commercial launch in Europe.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: